. 2018 Jun;7(3):436–444. doi: 10.21037/tau.2018.02.07

Table 1. Ongoing clinical trials with ²²³Ra in combination therapy.

Isotope	Combined therapy	NCT	Phase
²²³Ra	Niraparib (PARPi)	NCT03076203	1B
²²³Ra	Pembrolizumab (anti-PD1	NCT03093428	II
²²³Ra	Atezolizumab (anti-PDL1	NCT02814669	I
²²³Ra	Enzalutamide	NCT02194842	III
²²³Ra	Abiraterone/prednisone	NCT02043678	III
²²³Ra	Enzalutamide	NCT02225704	II

Table 1. Ongoing clinical trials with 223Ra in combination therapy.